Standard treatment for Methicillin-resistant Staphylococcus aureus (MRSA) infection is not more efficacious than combination therapy, according to new research published in JAMA. The CAMERA2 trial, discussed in the article, was terminated early for safety concerns.

Investigators from the Peter Doherty Institute for Infection and Immunity at the University of Melbourne conducted a randomized clinical trial across 27 hospital sites in 4 countries in order to determine if combination therapies would be more effective than standard therapy alone in patients with MRSA infections. The study took place between August 2015 and July 2018, included 352 hospitalized adults with MSRA. Originally, the investigators hoped to enroll 440 patients in the trial. The median age of participants was 64 years and baseline characteristics were similar between the 2 groups.

 

Image credit: CDC

Read more at Contagion…